Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.

Limone BL, Baker WL, Kluger J, Coleman CI.

PLoS One. 2013 Apr 23;8(4):e62183. doi: 10.1371/journal.pone.0062183. Print 2013. Review.

2.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
3.

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.

Shah A, Shewale A, Hayes CJ, Martin BC.

Stroke. 2016 Jun;47(6):1555-61. doi: 10.1161/STROKEAHA.115.012325. Epub 2016 Apr 21.

PMID:
27103018
4.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR.

Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.

5.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

6.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

7.

Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.

Liu CY, Chen HC.

Clin Drug Investig. 2017 Mar;37(3):285-293. doi: 10.1007/s40261-016-0487-7.

PMID:
27988835
8.

Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.

Verhoef TI, Redekop WK, Hasrat F, de Boer A, Maitland-van der Zee AH.

Am J Cardiovasc Drugs. 2014 Dec;14(6):451-62. doi: 10.1007/s40256-014-0092-1.

9.

Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation.

Limone BL, Baker WL, Mearns ES, White CM, Kluger J, Coleman CI.

J Clin Epidemiol. 2014 Oct;67(10):1093-102. doi: 10.1016/j.jclinepi.2014.05.013. Epub 2014 Jul 10. Review.

PMID:
25018102
10.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

11.

Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.

Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y.

Cardiovasc Drugs Ther. 2014 Dec;28(6):575-85. doi: 10.1007/s10557-014-6558-1.

PMID:
25319314
12.

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.

Am J Cardiol. 2012 Sep 15;110(6):845-51. doi: 10.1016/j.amjcard.2012.05.011. Epub 2012 May 30.

PMID:
22651881
13.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

14.

Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.

Wisløff T, Hagen G, Klemp M.

Pharmacoeconomics. 2014 Jun;32(6):601-12. doi: 10.1007/s40273-014-0152-z.

15.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.

Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.

16.

A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.

Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR.

Pharmacoeconomics. 2013 Jul;31(7):589-604. doi: 10.1007/s40273-013-0035-8.

17.

Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.

Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):472-9. doi: 10.1161/CIRCOUTCOMES.112.965251. Epub 2012 Jun 26.

18.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV.

Thromb Haemost. 2012 Oct;108(4):672-82. Epub 2012 Aug 17.

PMID:
22898892
19.
20.

Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Athanasakis K, Karampli E, Tsounis D, Bilitou A, Kyriopoulos J.

Clin Drug Investig. 2015 Nov;35(11):693-705. doi: 10.1007/s40261-015-0321-7.

PMID:
26385756

Supplemental Content

Support Center